Additional antianginal and anti-ischemic efficacy of Mibefradil in patients pretreated with a beta blocker for chronic stable angina pectoris

American Journal of Cardiology

Volumn 79, Issue 8, 1997, Pages 1025-1030

  Alpert, Joseph S ^a   Kobrin, Isaac ^b   DeQuattro, Vincent ^b   Friedman, Richard ^b   Shepherd, Alexander ^b   Fenster, Paul E ^b   Thadani, Udho ^b  

^a UNIVERSITY OF ARIZONA   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; GLYCERYL TRINITRATE; MIBEFRADIL; PLACEBO;

ADULT; AGED; ANGINA PECTORIS; ARTICLE; BLOOD PRESSURE MEASUREMENT; CLINICAL FEATURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; EXERCISE TEST; FEMALE; HEART RATE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; ST SEGMENT DEPRESSION; VERTIGO;

ADRENERGIC BETA-ANTAGONISTS; AGED; ANGINA PECTORIS; BENZIMIDAZOLES; CALCIUM CHANNEL BLOCKERS; CHRONIC DISEASE; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; EXERCISE TEST; FEMALE; HUMANS; MALE; MIBEFRADIL; MIDDLE AGED; TETRAHYDRONAPHTHALENES; TREATMENT OUTCOME; VASODILATOR AGENTS;

EID: 0030949998     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9149(97)00041-6     Document Type: Article

References (23)

1. 2+ channel blocker with potent vasodilator but weak inotropic action. J Cardiovasc Pharmacol 1989;13:754-759.
2. Rutledge A, Triggle D. The binding interaction of Ro 40-5967 at the L-type C channel in cardiac tissue. Eur J Pharmacol 1995;290:155-158.
3. Clozel J-P, Osterrieder W, Kleinbloesem C, Welker HA, Schläppi B, Tudor R, Hefti F, Schmitt R, Eggers H. Ro 40-5967: a new nondihydropyridine calcium antagonist. Cardiovasc Drug Rev 1991;9:4-17.
4. Welker H, Eggers H, Kleinbloesem C. Ro 40-5967, pharmacokinetics of a new calcium antagonist (abstr). Eur J Clin Pharmacol 1989;36:A304.
5. Bernink PJLM, Prager G, Schelling A, Kobrin I. Antihypertensive properties of the novel calcium antagonist mibefradil (Ro 40-5967). Hypertension 1996;27:426-432.
6. Bakx AL, van der Wall EE, Braun S, Emanuelsson H, Bruschke AV, Kobrin I. Effects of the new calcium antagonist mibefradil (Ro 40-5967) on exercise duration in patients with chronic stable angina pectoris: a multicenter, placebo-controlled study. Ro 40-5967 International Study Group. Am Heart J 1995;130:748-757.
7. Braun S, van der Wall EE, Emanuelsson H, Kobrin I. Effects of a new calcium antagonist, mibefradil (Ro 40-5967), on silent ischemia in patients with stable chronic angina pectoris: a multicenter placebo-controlled study. J Am Coll Cardiol 1996;27:317-333.
8. 2+ channel blocker Ro 40-5967, which binds to the [3H] desmethoxyverapamil receptor, is devoid of the negative inotropic effects of verapamil in normal and failing rat hearts. Cardiovasc Drugs Ther 1990;4:731-736.
9. Véniant M, Clozel J-P, Hess P, Wolfgang R. Ro 40-5967, in contrast to diltiazem, does not reduce left ventricular contractility in rats with chronic myocardial infarction. J Cardiovasc Pharmacol 1991;17:277-284.
10. Véniant M, Clozel J-P, Hess P, Wolfgang R. Hemodynamic profile of Ro 40-5967 in conscious rats: comparison with diltiazem, verapamil, and amlodipine. J Cardiovasc Pharmacol 1991;18(suppl 10):S55-S58.
11. Rousseau MF, Hayashida W, van Eyll C, Hess OM, Benedict CR, Ahn S, Chapelle F, Kobrin I, Pouleur H. Hemodynamic and cardiac effects of the selective T-type and L-type calcium channel blocker, mibefradil, in patients with varying degrees of left ventricular systolic dysfunction. J Am Coll Cardiol; 1996;28:972-979.
12. Portegies MC, Schmitt R, Kraaij CJ, Braat SH, Gassner A, Hagemeijer F, Pozenel H, Prager G, Viersma JW, van der Wall EE. Lack of negative inotropic effects of the new calcium antagonist Ro 40-5967 in patients with stable angina pectoris. J Cardiovasc Pharmacol 1991;18:746-751.
13. Anastassiades C. Nifedipine and β-blocker drugs. Br Med J 80;281:1251-1252.
14. Opie L, White D. Adverse interaction between nifedipine and β-blockade. Br Med J 1980;281:1462.
15. Ishikawa T, Imamura T, Koiwaya Y, Tanaka K. Atrioventricular dissociation and sinus arrest induced by oral diltiazem. N Engl J Med 1983;309:1124-1125.
16. Hossack K. Conduction abnormalities due to diltiazem. N Engl J Med 1982;307:953-954.
17. McGourty J, Silas J. β-blockers and verapamil: a cautionary tale. Br Med J 1984;289:1624.
18. Misra M, Thakur R, Bhandari K. Sinus arrest caused by atenolol-verapamil combination. Clin Cardiol 1987;10:365-367.
19. Strauss WE, Parisi AF. Combined use of calcium-channel and β adrenergic blockers for the treatment of chronic stable angina. Ann Intern Med 1988;109:571-581.
20. Packer M. Combined β-adrenergic and calcium-entry blockade in angina pectoris. N Engl J Med 1989;320:709-718.
21. Packer M, Meller J, Medina N, Yushak M, Smith H, Holt J, Guererro J, Todd GD, McAllister RG Jr, Gorlin R. Hemodynamic consequences of combined β-adrenergic and slow calcium-channel blockade in man. Circulation 1982;65:660-668.
22. Johnston D, Lesoway R, Humen D, Kostuk W. Clinical and hemodynamic evaluation of propranolol in combination with verapamil, nifedipine, and diltiazem in exertional angina pectoris: a placebo-controlled, double-blind randomized, crossover study. Am J Cardiol 1985;55:680-687.
23. Schmitt R, Kleinbloesem C, Belz GG, Schroeter V, Feifel U, Pozenel H, Kirch W, Halabi A, Woittiez A-J, Welker HA, van Brummelen P. Hemodynamic and humoral effect of the novel calcium antagonist Ro-5967 in patients with hypertension. Clin Pharmacol Ther 1992;52:314-323.